Viking Therapeutics Stock Forecast, Price & News

Viking Therapeutics (NASDAQ:VKTX) Frequently Asked Questions

Is Viking Therapeutics a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Viking Therapeutics stock.
View analyst ratings for Viking Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Viking Therapeutics?

Wall Street analysts have given Viking Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Viking Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Viking Therapeutics' next earnings date?

Viking Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.
View our earnings forecast for Viking Therapeutics.

How were Viking Therapeutics' earnings last quarter?

Viking Therapeutics, Inc. (NASDAQ:VKTX) posted its quarterly earnings results on Wednesday, July, 28th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.01.
View Viking Therapeutics' earnings history.

How has Viking Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Viking Therapeutics' stock was trading at $5.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VKTX stock has increased by 29.0% and is now trading at $6.54.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for VKTX?

5 analysts have issued twelve-month price objectives for Viking Therapeutics' stock. Their forecasts range from $13.00 to $21.00. On average, they expect Viking Therapeutics' stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 144.6% from the stock's current price.
View analysts' price targets for Viking Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Viking Therapeutics' key executives?

Viking Therapeutics' management team includes the following people:

• Brian Lian, President, Chief Executive Officer & Director
• Marianne Mancini, Chief Operating Officer
• Gregory S. Zante, Chief Financial & Accounting Officer
• Juliana Oliveira, Vice President-Clinical Development
• Michael Morneau, Vice President-Finance & Administration

Who are some of Viking Therapeutics' key competitors?

Some companies that are related to Viking Therapeutics include Organogenesis (ORGO), Xencor (XNCR), ADC Therapeutics (ADCT), Deciphera Pharmaceuticals (DCPH), Trillium Therapeutics (TRIL), NGM Biopharmaceuticals (NGM), MorphoSys (MOR), Centessa Pharmaceuticals (CNTA), IVERIC bio (ISEE), Prelude Therapeutics (PRLD), Global Blood Therapeutics (GBT), uniQure (QURE), Dicerna Pharmaceuticals (DRNA), Amneal Pharmaceuticals (AMRX) and Aerpio Pharmaceuticals (ARPO).
View all of VKTX's competitors.

What other stocks do shareholders of Viking Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), SCYNEXIS (SCYX), Amarin (AMRN), Advanced Micro Devices (AMD), Verastem (VSTM), Energy Transfer (ET) and Inovio Pharmaceuticals (INO).

When did Viking Therapeutics IPO?

(VKTX) raised $20 million in an initial public offering (IPO) on Wednesday, April 29th 2015. The company issued 2,500,000 shares at $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO and Feltl and Company was co-manager.

What is Viking Therapeutics' stock symbol?

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

Who are Viking Therapeutics' major shareholders?

Viking Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include ArrowMark Colorado Holdings LLC (9.81%), BlackRock Inc. (6.70%), State Street Corp (6.38%), Vanguard Group Inc. (4.20%), Geode Capital Management LLC (1.48%) and Fiera Capital Corp (1.39%). Company insiders that own Viking Therapeutics stock include Ligand Pharmaceuticals Inc and Matthew W Foehr.
View institutional ownership trends for Viking Therapeutics.

Which major investors are selling Viking Therapeutics stock?

VKTX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Ikarian Capital LLC, Rafferty Asset Management LLC, Citigroup Inc., Invesco Ltd., Bank of America Corp DE, BlackRock Inc., and Victory Capital Management Inc..
View insider buying and selling activity for Viking Therapeutics or view top insider-selling stocks.

Which major investors are buying Viking Therapeutics stock?

VKTX stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Goldman Sachs Group Inc., Geode Capital Management LLC, PDT Partners LLC, Bank of Montreal Can, Millennium Management LLC, and Parametric Portfolio Associates LLC.
View insider buying and selling activity for Viking Therapeutics or or view top insider-buying stocks.

How do I buy shares of Viking Therapeutics?

Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Viking Therapeutics' stock price today?

One share of VKTX stock can currently be purchased for approximately $6.54.

How much money does Viking Therapeutics make?

Viking Therapeutics has a market capitalization of $511.36 million. The biotechnology company earns $-39,490,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis.

How many employees does Viking Therapeutics have?

Viking Therapeutics employs 19 workers across the globe.

What is Viking Therapeutics' official website?

The official website for Viking Therapeutics is www.vikingtherapeutics.com.

Where are Viking Therapeutics' headquarters?

Viking Therapeutics is headquartered at 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130.

How can I contact Viking Therapeutics?

Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at (858) 704-4660 or via email at [email protected].